The use of alpha-synuclein in the development of animal models of PD has become popular in recent years, including the injection of alpha-synuclein pre-formed fibrils model and the recombinant adeno-associated virus vector-mediated alpha-synuclein overexpression model [64]. This evidence concerns the gene SNCA and Parkinson disease.